ArticleIndian journal of psychiatry2026
Economic barriers to psychiatric care: A comparative cost analysis of essential psychiatric drugs and Janaushadhi alternatives.
Article in Indian journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Access to affordable medications is an important determinant of treatment adherence and continuity of care. High out-of-pocket expenditure and cost disparities pose barriers and contribute to poor treatment adherence. Aim: We aimed to (1) analyze cost variation among different brands of essential psychiatric medications listed in the National List of Essential Medications (NLEM) 2022, and (2) compare market prices with corresponding generic drugs from the Janaushadhi Scheme. Methods: A cross-sectional price analysis was conducted using the current index of medical specialties (CIMS) and the Janaushadhi database. Results: There was high variation in market costs, ranging from 20.8% (Carbamazepine liquid) to 1604.4% (Clonazepam 0.5 mg). Median branded costs were higher than generic Janaushadhi prices. The cost ratio (branded price/generic price) was highest for Escitalopram 10 mg tablet (>7). Conclusion: Substantial price variation exists even among essential psychiatric medications, potentially undermining equitable access, particularly for economically disadvantaged groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.